Related Experiment Video
Updated: Oct 7, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Nivolumab induced hypophysitis in an advanced RCC patient
Merve Korkmaz Yilmaz1, Ilkay Gulturk2, Seher Yildiz Tacar2
1Internal Medicine Department, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
Introduction:
Immune checkpoint inhibitors (ICIs) are being commonly used to treat solid tumours such as renal cell carcinoma. Hypophysitis is an acute or chronic inflammation of the pituitary gland and nivolumab or pembrolizumab induced hypophysitis is markedly lower compared to ipilimumab.
Case Report:
We present a novel case of a patient with mRCC who was diagnosed with nivolumab induced hypophysitis based on clinical suspicion due to his hormonal profile and a range of symptoms that he developed during nivolumab immunotherapy.
Management And Outcome:
He was treated with high dose of hydrocortisone administered intravenously, subsequently changed to the oral route and physiologic dose.
Discussion:
Nivolumab induced hypophysitis is a rare condition that usually presents with fewer symptoms. High degree of clinical suspicion and a multidisciplinary team required to diagnose and treat such cases.
Related Concept Videos
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Tumor Immunotherapy
Chronic Kidney Disease II: Clinical Manifestations
Kidney Transplant III: Nursing Management
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...

